{"gene":"ERAP2","run_date":"2026-06-09T23:54:43","timeline":{"discoveries":[{"year":2005,"finding":"ERAP1 and ERAP2 form heterodimeric complexes in the endoplasmic reticulum and act with concerted, complementary aminopeptidase activities to trim N-terminally extended peptide precursors for HLA class I presentation; ERAP2 efficiently removed N-terminal residues that ERAP1 could not trim, and combined action was required both in vitro and in vivo for full processing of some epitopes.","method":"Co-localization in vivo, physical co-immunoprecipitation demonstrating heterodimer formation, in vitro peptide digestion assays comparing single vs. dual enzyme activity, cellular antigen presentation assays","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP establishing physical interaction, orthogonal in vitro and in vivo functional assays, foundational study replicated by multiple subsequent labs","pmids":["15908954"],"is_preprint":false},{"year":2014,"finding":"ERAP1-ERAP2 heterodimer formation increases peptide-trimming efficiency above that of a mixture of the two enzymes unable to dimerize; physical interaction with ERAP2 changes basic enzymatic parameters of ERAP1 and improves its substrate-binding affinity through allosteric effects.","method":"Production of stabilized ERAP1-ERAP2 heterodimers; comparison of peptide-trimming kinetics (epitope production) between heterodimers and non-dimerizing enzyme mixtures; enzymatic parameter measurement","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — in vitro reconstitution with stabilized heterodimers plus kinetic analysis, single lab but multiple orthogonal measurements of enzymatic parameters","pmids":["24928998"],"is_preprint":false},{"year":2016,"finding":"ERAP1/ERAP2 heterodimers can trim MHC class I-bound precursor peptides (not only free peptides) to their correct final lengths, albeit more slowly than free precursors; trimming of MHC I-bound precursors by ERAP1/2 increases the conformational stability of MHC I/peptide complexes.","method":"In vitro trimming assays using purified ERAP1/ERAP2 heterodimers with free and HLA-B*0801-bound N-terminally extended model and natural peptides; conformational stability measurements of MHC I/peptide complexes","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution assay with defined substrates (free and MHC-bound), heterodimer system, multiple peptide substrates tested","pmids":["27514473"],"is_preprint":false},{"year":2010,"finding":"A splice variant of ERAP2 encoded by Haplotype B undergoes nonsense-mediated decay (NMD), resulting in ERAP2 protein deficiency; Haplotype B homozygotes have lower levels of MHC class I on B cell surfaces compared to Haplotype A homozygotes, demonstrating that naturally occurring ERAP2 deficiency affects MHC class I antigen presentation.","method":"Population genetic analysis of six human populations; RT-PCR demonstrating differential splicing; correlation of surface MHC class I expression with ERAP2 genotype in primary lymphocytes by flow cytometry","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — genotype-phenotype correlation with functional cellular readout across multiple populations, splicing mechanism established by direct RT-PCR, replicated in independent cohorts","pmids":["20976248"],"is_preprint":false},{"year":2017,"finding":"ERAP1 and ERAP2 have significant and largely distinct effects on the HLA-B*27:05 peptidome in human cells; ERAP1 increases the proportion of nonamers relative to longer ligands and reduces Ala1 usage, while ERAP2 (in a low-activity ERAP1 context) additionally reduces peptides with N-terminal basic residues and lowers overall peptidome affinity. Both enzymes largely act as separate entities in vivo rather than obligate partners.","method":"Quantitative mass spectrometry comparison of HLA-B*27:05 peptidomes from cells with various ERAP1/ERAP2 phenotypes; label-free quantitative proteomics","journal":"Journal of autoimmunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — quantitative immunopeptidomics in live cells with multiple ERAP phenotype combinations, replicated across cell lines with different genetic backgrounds","pmids":["28063628"],"is_preprint":false},{"year":2019,"finding":"ERAP2 deletion from HLA-B*51:01-expressing cells by CRISPR/Cas9 reduces HLA-B*51 surface expression and alters the B*51:01 peptidome; in the absence of ERAP1, ERAP2 alone shows significant processing of B*51:01 ligands (functional redundancy), but effects of each enzyme differ substantially, revealing mutual dependence and partially redundant roles.","method":"CRISPR/Cas9 knockout of ERAP1, ERAP2, or both in transfectant 721.221-HLA-B*51:01 cells; label-free quantitative mass spectrometry comparison of HLA-B*51:01 peptidomes","journal":"Molecular & cellular proteomics","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean CRISPR KO with reciprocal single and double knockouts, quantitative immunopeptidomics, multiple orthogonal comparisons","pmids":["31092671"],"is_preprint":false},{"year":2018,"finding":"ERAP2 expression alters the HLA-A*29:02 peptidome by increasing peptides >9-mers and shifting N-terminal residue composition toward less ERAP2-susceptible and more hydrophobic residues; unproductive ERAP2 binding may protect some peptides from ERAP1 over-trimming. ERAP2 effects are allele-specific and differ from its effects on HLA-B*27.","method":"Lentiviral transduction of ERAP2 into ERAP2-negative cells; label-free quantitative mass spectrometry of A*29:02-bound peptidomes; comparison across two independent A*29:02-positive cell lines","journal":"Molecular & cellular proteomics","confidence":"High","confidence_rationale":"Tier 2 / Strong — gain-of-function lentiviral system with quantitative immunopeptidomics, replicated in two independent cell line comparisons","pmids":["29769354"],"is_preprint":false},{"year":2020,"finding":"ERAP2 CRISPR knockout in cells expressing HLA-B*27:05 alters the natural ligandome: absence of ERAP2 enriches peptides with N-terminal basic residues and minority canonical P2 residues, and affects hydrophobicity profiles at P3, P7, and PΩ positions; one ERAP2-dependent human peptide was found fully conserved in a Campylobacter jejuni protein (potential molecular mimicry).","method":"CRISPR/Cas9 editing of ERAP2 in human cells; high-throughput and quantitative tandem mass spectrometry of HLA-B*27:05-bound peptidome; bioinformatics sequence alignment to arthritogenic bacteria","journal":"Molecular & cellular proteomics","confidence":"High","confidence_rationale":"Tier 2 / Moderate — clean CRISPR KO with quantitative immunopeptidomics, single lab, multiple analytical approaches","pmids":["32265295"],"is_preprint":false},{"year":2022,"finding":"The optimal ligands for ERAP1 (octamers) act as competitive inhibitors of ERAP2 activity, while peptides longer than nonamers inhibit ERAP1; ERAP1 and ERAP2 thus synergize to self-modulate their respective activities and jointly shape the MHC-I peptidome toward optimal peptide lengths.","method":"Biochemical inhibition assays with defined peptide substrates; proteomic studies; biological verification of inhibition model","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 1-2 / Weak — in vitro biochemical and proteomic data from single lab, mechanism supported but limited independent replication","pmids":["36569828"],"is_preprint":false},{"year":2013,"finding":"ERAP1 and ERAP2 show concerted in vitro trimming of HLA-B27-restricted viral ligand precursors: each enzyme can use the degradation products of the other as substrates, resulting in increased detection of natural HLA-B27 ligands with combined versus single enzyme digestion.","method":"In vitro peptide digestion comparing single ERAP1, single ERAP2, and combined ERAP1+ERAP2 digestions; mass spectrometry identification of peptide products","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro reconstitution assay with mass spectrometry readout, single lab, limited substrate set","pmids":["24223975"],"is_preprint":false},{"year":2019,"finding":"ERAP2 depletion (CRISPR KO) from HLA-B*40:02-expressing cells induces significant quantitative changes in the HLA-B*40:02 peptidome; the major effect is on N-terminal residue frequencies—basic and small residues increased, aliphatic/aromatic decreased—consistent with ERAP2's preferential trimming of N-terminal basic residues.","method":"CRISPR/Cas9 knockout of ERAP2 in C1R-B*40:02 transfectant cells; label-free quantitative mass spectrometry comparison of wildtype vs. ERAP2-KO peptidomes","journal":"Molecular & cellular proteomics","confidence":"High","confidence_rationale":"Tier 2 / Moderate — clean CRISPR KO, quantitative immunopeptidomics, mechanistic characterization of substrate preferences, single lab","pmids":["31530632"],"is_preprint":false},{"year":2021,"finding":"ERAP2 generates a peptide submotif specifically bound by HLA-A29 (not by other HLA allotypes tested); this ERAP2-dependent peptide motif is present in sequences of putative autoantigens, and ERAP2 imprints internal sequence specificity in the immunopeptidome.","method":"HLA-A29-based and pan-class I immunopurifications in patient-derived antigen-presenting cells; isotope-labeled quantitative mass spectrometry of naturally processed and presented HLA-bound peptides; replicated in independent datasets","journal":"Frontiers in immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — quantitative immunopeptidomics in patient-derived cells, findings replicated in independent experiment, multiple HLA allotype comparisons","pmids":["33717175"],"is_preprint":false},{"year":2022,"finding":"ERAP2 inhibition with a selective small-molecule inhibitor in MOLT-4 leukemia cells induces significant shifts in the MHC class I immunopeptidome; >20% of detected peptides were novel or significantly upregulated, with most inhibitor-induced peptides being 9-mers with appropriate HLA-binding motifs, providing evidence that ERAP2 enzymatic activity shapes the cancer cell immunopeptidome.","method":"Pharmacological ERAP2 inhibition in MOLT-4 cells; MHC class I immunopurification; LC-MS/MS sequencing of bound peptides","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — pharmacological perturbation with quantitative immunopeptidomics, single lab, inhibitor selectivity relied on prior validation","pmids":["35163832"],"is_preprint":false},{"year":2022,"finding":"Crystal structure of ERAP2 bound to a novel phenylsulfamoyl benzoic acid inhibitor (compound 61) revealed it binds near the catalytic center at a site distinct from peptidomimetic inhibitors and inhibits by an uncompetitive mechanism; active-site residue specificity determinants were identified: His904 in an allosteric site of ERAP2 governs binding and the absence of activation by compound 3 (H904A mutation reveals a cryptic allosteric site), while ERAP1 Lys380 in the S1' pocket governs binding of related compounds.","method":"Co-crystallization and X-ray crystal structure determination of ERAP2-inhibitor complex; enzyme kinetics (uncompetitive mechanism); site-directed mutagenesis of active site and allosteric residues","journal":"ACS chemical biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure plus mutagenesis plus kinetic mechanism determination in a single study, multiple orthogonal methods","pmids":["35767698"],"is_preprint":false},{"year":2022,"finding":"Kinetic target-guided synthesis identified the first nanomolar, selective ERAP2 inhibitors; co-crystallization experiments revealed the binding mode of three inhibitors with increasing potency and selectivity; selected compounds engage ERAP2 in cells and inhibit antigen presentation in a cellular context.","method":"Kinetic target-guided synthesis; co-crystallization with X-ray structure determination; cellular ERAP2 engagement assays; cellular antigen presentation inhibition assays","journal":"Angewandte Chemie","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structures plus cellular functional assays, multiple inhibitor structures determined, single lab but orthogonal methods","pmids":["35904863"],"is_preprint":false},{"year":2020,"finding":"ERAP2 knockdown in pancreatic stellate cells inhibits unfolded protein response (UPR)-mediated autophagy, leading to PSC inactivation and attenuation of IL-6 and fibronectin production; in vivo, ERAP2 knockdown in PSCs inhibited xenograft tumor growth and fibrosis.","method":"siRNA knockdown of ERAP2 in patient-derived pancreatic stellate cells; measurement of UPR markers, autophagy, IL-6, and fibronectin; orthotopic xenograft mouse model with ERAP2-knockdown PSCs","journal":"Pancreatology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — loss-of-function with defined cellular and in vivo phenotype, single lab, pathway (UPR-autophagy) established but upstream mechanism linking ERAP2 aminopeptidase activity to UPR not fully elucidated","pmids":["34642112"],"is_preprint":false},{"year":2022,"finding":"ERAP2 is secreted from activated macrophages (stimulated with IFNγ/LPS) as detected by mass spectrometry of the secretome; the secreted full-length recombinant ERAP2 reduces HIV-1 replication in PBMCs in vitro (statistically significant), associated with increased IFNγ and CD69 expression and increased perforin-expressing CD107+CD8+ T cells.","method":"Mass spectrometry of MDM secretome after IFNγ/LPS stimulation; addition of recombinant human ERAP2 to PBMC cultures; HIV-1 p24 viral antigen quantification; flow cytometry for T cell markers","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2-3 / Weak — mass spectrometry confirms secretion, functional anti-HIV effect demonstrated in vitro with recombinant protein, single lab","pmids":["31379846"],"is_preprint":false},{"year":2022,"finding":"ERAP2 expression is directly regulated by the splice region variant rs2248374 (established by reciprocal allelic replacement); disease-associated variants in the downstream LNPEP gene promoter independently regulate ERAP2 expression through long-range chromatin contacts, with allele-specific conformation capture assays showing stronger LNPEP-ERAP2 promoter interactions in autoimmune disease-risk allele carriers.","method":"Reciprocal allelic replacement (CRISPR-based); allele-specific chromosome conformation capture (4C/Hi-C); ERAP2 expression quantification by allele replacement","journal":"Cell genomics","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal allelic replacement establishes direct causal link, complemented by chromatin conformation capture, two independent regulatory mechanisms identified","pmids":["38190099"],"is_preprint":false},{"year":2020,"finding":"An alternative ERAP2 isoform (ERAP2/Iso3) is expressed from the rs2248374-G haplotype in response to multiple microbial stimuli (influenza, LPS, CMV, HIV, SARS-CoV-2 antigens); unlike ERAP2-wt, ERAP2/Iso3 is unable to trim peptides for MHC class I loading but can still dimerize with both ERAP2-wt and ERAP1-wt; ERAP2/Iso3 mRNA is translated into protein.","method":"RT-qPCR of ERAP2/Iso3 mRNA in stimulated PBMCs and MDMs; western blot confirmation of protein translation; in vitro peptide trimming assay demonstrating loss of function; dimerization assessment","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2-3 / Weak — mRNA and protein confirmed, loss-of-trimming function established, dimerization capacity reported, single lab","pmids":["32847031"],"is_preprint":false},{"year":2022,"finding":"Macrophages (but not monocytes or other blood mononuclear cells) express and secrete an ERAP2 'short' form independent of haplotype; this short form is generated by autocatalytic cleavage within a distinctive structural motif requiring an acidic microenvironment; the short ERAP2 binds IRAP and both molecules are co-expressed in endosomes and on the cell membrane.","method":"Western blot detecting short ERAP2 form in macrophage lysates and secretome; autocatalytic cleavage demonstrated with recombinant protein under acidic conditions; co-immunoprecipitation of short ERAP2 with IRAP; co-localization by immunofluorescence in endosomes and cell membrane","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2-3 / Weak — autocatalytic mechanism supported biochemically, IRAP binding by Co-IP, co-localization data, single lab","pmids":["35563348"],"is_preprint":false},{"year":2013,"finding":"EpCAM co-immunoprecipitates with ERAP2 in breast cancer cell lines and the two proteins co-localize in the cytoplasm/ER and at the plasma membrane; in vitro expression in ER vesicles confirmed N-linked glycosylation and ER processing of EpCAM, suggesting ERAP2 may regulate EpCAM processing.","method":"Co-immunoprecipitation followed by mass spectrometry; in vitro expression in dog pancreas rough microsomes (ER vesicles); co-localization imaging","journal":"Biochemical and biophysical research communications","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single Co-IP/MS identification, no functional validation of the interaction's consequence, single lab","pmids":["23988446"],"is_preprint":false},{"year":2016,"finding":"A regulatory variant (rs75862629 G vs. A) in the ERAP2 gene promoter region inversely coordinates expression of ERAP1 and ERAP2: presence of G at this SNP results in down-modulation of ERAP2 coupled with significantly higher ERAP1 expression in B-lymphoblastoid cell lines.","method":"Correlation of ERAP1 and ERAP2 transcript and protein levels with promoter region SNP genotype across 44 B-lymphoblastoid cell line donors; quantitative RT-PCR and protein quantification","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — expression quantification correlated with genotype across 44 donors, both mRNA and protein measured, but causal mechanism not directly tested by allelic replacement","pmids":["29991817"],"is_preprint":false},{"year":2023,"finding":"ERAP2, when expressed alone in ERAP-deficient cells, elicits a strong CTL response to the Tyrosinase368-376 HLA-A*02:01-restricted tumor epitope; ERAP2 alone can process TAP-dependent N-terminally extended epitope precursors of Tyrosinase368-376 in vitro; ERAP2 also independently enhances T cell recognition of gp100209-217 and MART-126/27-35 epitopes in the absence of ERAP1.","method":"Expression of ERAP2 alone in ERAP-deficient cells; CTL activation assays; in vitro peptide trimming assays with defined precursor peptides; T cell recognition assays","journal":"Molecular immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — in vitro trimming plus cellular CTL assay, multiple epitopes tested, single lab","pmids":["36608422"],"is_preprint":false}],"current_model":"ERAP2 is an ER-resident zinc aminopeptidase that trims N-terminally extended peptide precursors for MHC class I loading, with preferential activity toward peptides bearing N-terminal basic residues and toward shorter (<9-mer) substrates; it physically associates with ERAP1 to form heterodimers that exhibit enhanced trimming efficiency and allosterically modified ERAP1 kinetics, and can also trim MHC-I-bound precursors directly, with the two enzymes showing largely distinct but partially redundant and mutually inhibitory activities that together optimize the HLA class I immunopeptidome in an allotype-specific manner; expression of ERAP2 is controlled by a splice-region variant (rs2248374) causing nonsense-mediated decay of one haplotype, and by long-range chromatin contacts from the LNPEP promoter region; additionally, a macrophage-specific autocatalytically generated short form of ERAP2 binds IRAP in endosomes and at the cell membrane, and ERAP2 can be secreted extracellularly where it modulates immune responses including reducing HIV-1 replication."},"narrative":{"mechanistic_narrative":"ERAP2 is an endoplasmic reticulum-resident zinc aminopeptidase that trims N-terminally extended peptide precursors to optimize the HLA class I immunopeptidome [PMID:15908954, PMID:31092671]. It acts in concert with ERAP1, forming heterodimers in the ER whose assembly increases trimming efficiency above that of the unassociated enzymes and allosterically improves ERAP1 substrate-binding affinity [PMID:15908954, PMID:24928998]; the heterodimer can trim not only free precursors but also MHC class I-bound precursors, increasing the conformational stability of the resulting MHC/peptide complexes [PMID:27514473]. Functionally, ERAP2 shows a characteristic preference for removing N-terminal basic residues, and its activity is largely distinct from, yet partially redundant with, that of ERAP1 — each enzyme can consume the other's products, and their optimal substrates competitively inhibit one another so that the two activities self-modulate toward optimal peptide lengths [PMID:24223975, PMID:36569828, PMID:31530632]. Across multiple HLA allotypes (B*27:05, A*29:02, B*51:01, B*40:02), ERAP2 perturbation reshapes N-terminal residue usage, peptide length distributions, and overall binding affinity, and ERAP2 alone can generate functional tumor and viral epitopes in the absence of ERAP1, including imprinting allotype-restricted internal sequence motifs [PMID:28063628, PMID:29769354, PMID:31092671, PMID:32265295, PMID:33717175]. ERAP2 expression is genetically controlled: the splice-region variant rs2248374 directs a haplotype B transcript to nonsense-mediated decay, producing protein deficiency that lowers surface MHC class I, and disease-associated variation in the downstream LNPEP promoter independently regulates ERAP2 via long-range chromatin contacts [PMID:20976248, PMID:38190099]. Beyond canonical antigen processing, a macrophage-specific short form of ERAP2 is generated by autocatalytic cleavage under acidic conditions and binds IRAP in endosomes and at the cell membrane, and full-length ERAP2 is secreted from activated macrophages where it reduces HIV-1 replication in PBMCs [PMID:35563348, PMID:31379846]. Crystallographic and inhibitor studies have defined ERAP2 active-site and allosteric determinants and yielded selective nanomolar inhibitors that engage the enzyme in cells and block antigen presentation [PMID:35767698, PMID:35904863].","teleology":[{"year":2005,"claim":"Established that ERAP2 is not an isolated aminopeptidase but physically partners with ERAP1 to complete peptide trimming, answering how distinct trimming specificities are integrated for HLA class I presentation.","evidence":"Co-localization, reciprocal Co-IP, in vitro digestion, and cellular antigen presentation assays","pmids":["15908954"],"confidence":"High","gaps":["Stoichiometry and structural basis of the heterodimer not resolved","Did not quantify allosteric kinetic changes"]},{"year":2010,"claim":"Showed that a naturally occurring splice variant routes one ERAP2 haplotype to NMD, defining the genetic basis of ERAP2 deficiency and linking it to reduced surface MHC class I.","evidence":"Population genetics, RT-PCR splicing analysis, and flow cytometry of surface MHC I across genotypes","pmids":["20976248"],"confidence":"High","gaps":["Specific epitopes lost in deficiency not mapped","Mechanism by which deficiency alters disease risk not addressed"]},{"year":2013,"claim":"Demonstrated concerted, sequential processing in which each enzyme uses the other's products, clarifying how ERAP1 and ERAP2 cooperate at the substrate level.","evidence":"In vitro single vs. combined ERAP1/ERAP2 digestion with MS product identification; Co-IP/MS in breast cancer cells for an EpCAM interaction","pmids":["24223975","23988446"],"confidence":"Medium","gaps":["Limited substrate set in trimming assays","EpCAM interaction is a single Co-IP/MS without functional validation"]},{"year":2014,"claim":"Reconstitution of stabilized heterodimers established that dimerization itself, not mere enzyme co-presence, enhances trimming and allosterically reshapes ERAP1 kinetics.","evidence":"Stabilized ERAP1-ERAP2 heterodimers vs. non-dimerizing mixtures with kinetic measurement","pmids":["24928998"],"confidence":"High","gaps":["In vivo prevalence of heterodimers vs. monomers not quantified","Structural interface not defined"]},{"year":2016,"claim":"Extended ERAP function to MHC-bound precursors, showing trimming can occur on loaded complexes and improves their stability, refining the timing of editing in the loading pathway.","evidence":"In vitro trimming of free and HLA-B*0801-bound precursors with conformational stability assays","pmids":["27514473"],"confidence":"High","gaps":["Relative in vivo contribution of bound vs. free trimming unknown","Single HLA allotype tested"]},{"year":2018,"claim":"Defined ERAP2's allotype-specific imprint on the immunopeptidome, showing largely distinct effects from ERAP1 and a possible protective role against ERAP1 over-trimming.","evidence":"Quantitative immunopeptidomics of HLA-B*27:05 and HLA-A*29:02 with ERAP perturbation across cell lines","pmids":["28063628","29769354"],"confidence":"High","gaps":["Mechanism of 'unproductive binding' protection inferred, not directly shown","Effects compared across only a few allotypes"]},{"year":2020,"claim":"CRISPR knockouts across multiple HLA allotypes nailed ERAP2's substrate signature — preferential N-terminal basic-residue trimming — and revealed partial redundancy with mutual dependence on ERAP1.","evidence":"Reciprocal CRISPR KO of ERAP1/ERAP2 in HLA-B*51:01 and B*40:02 cells with quantitative immunopeptidomics","pmids":["31092671","31530632"],"confidence":"High","gaps":["Molecular basis of substrate preference not structurally explained here","Functional consequences for T-cell repertoire not measured"]},{"year":2020,"claim":"Identified non-canonical ERAP2 biology: a microbially induced, trimming-dead isoform that still dimerizes, and a UPR/autophagy-linked role in pancreatic stellate cells.","evidence":"RT-qPCR/western of ERAP2/Iso3 with trimming and dimerization assays; siRNA knockdown in PSCs with xenograft model","pmids":["32847031","34642112"],"confidence":"Medium","gaps":["Functional purpose of trimming-dead Iso3 dimers unknown","How ERAP2 aminopeptidase activity links to UPR/autophagy not mechanistically established"]},{"year":2021,"claim":"Showed ERAP2 imprints internal (not just N-terminal) sequence specificity, generating allotype-restricted submotifs relevant to autoantigen presentation.","evidence":"Quantitative immunopeptidomics in patient-derived APCs across HLA allotypes, replicated","pmids":["33717175"],"confidence":"High","gaps":["Causal link between submotif and autoimmunity not established","Restricted to HLA-A29 context"]},{"year":2022,"claim":"Resolved the self-modulation logic: ERAP1's optimal substrates inhibit ERAP2 and vice versa, explaining how the pair converges on optimal peptide lengths.","evidence":"Biochemical inhibition assays with defined peptides plus proteomic verification","pmids":["36569828"],"confidence":"Medium","gaps":["Single lab, limited independent replication","Inhibition constants in cellular context not measured"]},{"year":2022,"claim":"Structural and inhibitor work defined ERAP2 active-site and allosteric determinants and produced selective cell-active inhibitors, enabling pharmacological dissection of ERAP2 in antigen presentation.","evidence":"Co-crystallization, enzyme kinetics, site-directed mutagenesis, and cellular engagement/antigen presentation assays","pmids":["35767698","35904863","35163832"],"confidence":"High","gaps":["Inhibitor effects on full immunopeptidome only partially mapped","Allosteric site His904 function beyond compound binding unclear"]},{"year":2022,"claim":"Characterized extracellular and macrophage-specific ERAP2 forms, expanding its role beyond intracellular peptide editing to secreted immunomodulation and IRAP binding.","evidence":"Secretome MS, recombinant ERAP2 anti-HIV assays in PBMCs, autocatalytic cleavage and IRAP Co-IP/co-localization in macrophages","pmids":["31379846","35563348"],"confidence":"Medium","gaps":["Mechanism of extracellular anti-HIV action not defined","Physiological function of the short ERAP2-IRAP complex unknown"]},{"year":2023,"claim":"Demonstrated that ERAP2 alone can generate functional tumor epitopes, establishing an ERAP1-independent contribution to CTL recognition.","evidence":"ERAP2 expression in ERAP-deficient cells, in vitro precursor trimming, and CTL/T-cell recognition assays for Tyrosinase, gp100, and MART-1 epitopes","pmids":["36608422"],"confidence":"Medium","gaps":["Single lab","Breadth of ERAP2-independent epitope generation across tumors not assessed"]},{"year":2024,"claim":"Established two independent causal regulatory mechanisms for ERAP2 expression — the rs2248374 splice variant and long-range LNPEP promoter chromatin contacts — connecting expression control to autoimmune disease risk.","evidence":"Reciprocal CRISPR allelic replacement and allele-specific chromosome conformation capture","pmids":["38190099"],"confidence":"High","gaps":["Downstream immune consequences of altered expression in carriers not measured","Interplay between the two regulatory mechanisms not resolved"]},{"year":null,"claim":"How ERAP2's multiple non-canonical activities — secreted immunomodulation, the IRAP-bound macrophage short form, trimming-dead dimerizing isoforms, and UPR/autophagy effects — integrate with its core role in MHC class I peptide editing remains unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No unified model connecting intracellular trimming and extracellular/non-canonical roles","Physiological relevance of macrophage short form and IRAP complex undefined","Mechanistic basis of UPR/autophagy link untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,2,9,10]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,1,9,13]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[1,8]}],"localization":[{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[0,2,20]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[19]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[19,20]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[16,19]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,3,4,5,16]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[0,2,9]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[3,17]}],"complexes":["ERAP1-ERAP2 heterodimer"],"partners":["ERAP1","IRAP","EPCAM"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q6P179","full_name":"Endoplasmic reticulum aminopeptidase 2","aliases":["Leukocyte-derived arginine aminopeptidase","L-RAP"],"length_aa":960,"mass_kda":110.5,"function":"Aminopeptidase that plays a central role in peptide trimming, a step required for the generation of most HLA class I-binding peptides. Peptide trimming is essential to customize longer precursor peptides to fit them to the correct length required for presentation on MHC class I molecules. Preferentially hydrolyzes the basic residues Arg and Lys","subcellular_location":"Endoplasmic reticulum membrane","url":"https://www.uniprot.org/uniprotkb/Q6P179/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ERAP2","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ERAP2","total_profiled":1310},"omim":[{"mim_id":"609497","title":"ENDOPLASMIC RETICULUM AMINOPEPTIDASE 2; ERAP2","url":"https://www.omim.org/entry/609497"},{"mim_id":"609423","title":"HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/609423"},{"mim_id":"606832","title":"ENDOPLASMIC RETICULUM AMINOPEPTIDASE 1; ERAP1","url":"https://www.omim.org/entry/606832"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Golgi apparatus","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":46.5}],"url":"https://www.proteinatlas.org/search/ERAP2"},"hgnc":{"alias_symbol":["L-RAP","LRAP"],"prev_symbol":[]},"alphafold":{"accession":"Q6P179","domains":[{"cath_id":"2.60.40.1730","chopping":"55-271","consensus_level":"medium","plddt":97.9392,"start":55,"end":271},{"cath_id":"-","chopping":"474-536","consensus_level":"medium","plddt":84.833,"start":474,"end":536},{"cath_id":"2.60.40.1910","chopping":"554-652","consensus_level":"high","plddt":96.7585,"start":554,"end":652}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q6P179","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q6P179-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q6P179-F1-predicted_aligned_error_v6.png","plddt_mean":93.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ERAP2","jax_strain_url":"https://www.jax.org/strain/search?query=ERAP2"},"sequence":{"accession":"Q6P179","fasta_url":"https://rest.uniprot.org/uniprotkb/Q6P179.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q6P179/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q6P179"}},"corpus_meta":[{"pmid":"15908954","id":"PMC_15908954","title":"Concerted peptide trimming by human ERAP1 and ERAP2 aminopeptidase complexes in the endoplasmic reticulum.","date":"2005","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15908954","citation_count":383,"is_preprint":false},{"pmid":"20976248","id":"PMC_20976248","title":"Balancing selection maintains a form of ERAP2 that undergoes nonsense-mediated decay and affects antigen presentation.","date":"2010","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20976248","citation_count":196,"is_preprint":false},{"pmid":"30425713","id":"PMC_30425713","title":"How ERAP1 and ERAP2 Shape the Peptidomes of Disease-Associated MHC-I Proteins.","date":"2018","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30425713","citation_count":136,"is_preprint":false},{"pmid":"8250931","id":"PMC_8250931","title":"Amelogenin post-translational modifications: carboxy-terminal processing and the phosphorylation of bovine and porcine \"TRAP\" and \"LRAP\" amelogenins.","date":"1993","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/8250931","citation_count":106,"is_preprint":false},{"pmid":"1996994","id":"PMC_1996994","title":"Identification of the leucine-rich amelogenin peptide (LRAP) as the translation product of an alternatively spliced transcript.","date":"1991","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/1996994","citation_count":104,"is_preprint":false},{"pmid":"24957906","id":"PMC_24957906","title":"A genome-wide association study identifies a functional ERAP2 haplotype associated with birdshot chorioretinopathy.","date":"2014","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24957906","citation_count":102,"is_preprint":false},{"pmid":"15299015","id":"PMC_15299015","title":"The COOH terminus of the amelogenin, LRAP, is oriented next to the hydroxyapatite surface.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15299015","citation_count":100,"is_preprint":false},{"pmid":"19433412","id":"PMC_19433412","title":"Association of an ERAP1 ERAP2 haplotype with familial ankylosing spondylitis.","date":"2009","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/19433412","citation_count":90,"is_preprint":false},{"pmid":"19578876","id":"PMC_19578876","title":"The ERAP2 gene is associated with preeclampsia in Australian and Norwegian populations.","date":"2009","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19578876","citation_count":84,"is_preprint":false},{"pmid":"18393273","id":"PMC_18393273","title":"Altered expression of endoplasmic reticulum aminopeptidases ERAP1 and ERAP2 in transformed non-lymphoid human tissues.","date":"2008","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/18393273","citation_count":83,"is_preprint":false},{"pmid":"27514473","id":"PMC_27514473","title":"ERAP1-ERAP2 dimers trim MHC I-bound precursor peptides; implications for understanding peptide editing.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27514473","citation_count":82,"is_preprint":false},{"pmid":"24928998","id":"PMC_24928998","title":"ERAP1-ERAP2 dimerization increases peptide-trimming efficiency.","date":"2014","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/24928998","citation_count":71,"is_preprint":false},{"pmid":"30446528","id":"PMC_30446528","title":"Genetic analysis of isoform usage in the human anti-viral response reveals influenza-specific regulation of ERAP2 transcripts under balancing selection.","date":"2018","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/30446528","citation_count":58,"is_preprint":false},{"pmid":"21569342","id":"PMC_21569342","title":"Fetal ERAP2 variation is associated with preeclampsia in African Americans in a case-control study.","date":"2011","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21569342","citation_count":56,"is_preprint":false},{"pmid":"32135401","id":"PMC_32135401","title":"The roles of ERAP1 and ERAP2 in autoimmunity and cancer immunity: New insights and perspective.","date":"2020","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32135401","citation_count":53,"is_preprint":false},{"pmid":"30825518","id":"PMC_30825518","title":"Regulation of ERAP1 and ERAP2 genes and their disfunction in human cancer.","date":"2019","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30825518","citation_count":51,"is_preprint":false},{"pmid":"28759104","id":"PMC_28759104","title":"The interplay between HLA-B27 and ERAP1/ERAP2 aminopeptidases: from anti-viral protection to spondyloarthritis.","date":"2017","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28759104","citation_count":51,"is_preprint":false},{"pmid":"28063628","id":"PMC_28063628","title":"Separate effects of the ankylosing spondylitis associated ERAP1 and ERAP2 aminopeptidases determine the influence of their combined phenotype on the HLA-B*27 peptidome.","date":"2017","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/28063628","citation_count":50,"is_preprint":false},{"pmid":"30414458","id":"PMC_30414458","title":"Intracellular antigen processing by ERAP2: Molecular mechanism and roles in health and disease.","date":"2018","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30414458","citation_count":49,"is_preprint":false},{"pmid":"30215709","id":"PMC_30215709","title":"Functionally distinct ERAP1 and ERAP2 are a hallmark of HLA-A29-(Birdshot) Uveitis.","date":"2018","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30215709","citation_count":47,"is_preprint":false},{"pmid":"30797823","id":"PMC_30797823","title":"Influence of ERAP1 and ERAP2 gene polymorphisms on disease susceptibility in different populations.","date":"2019","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30797823","citation_count":47,"is_preprint":false},{"pmid":"18192371","id":"PMC_18192371","title":"The structure and orientation of the C-terminus of LRAP.","date":"2008","source":"Biophysical journal","url":"https://pubmed.ncbi.nlm.nih.gov/18192371","citation_count":38,"is_preprint":false},{"pmid":"32793222","id":"PMC_32793222","title":"The Multifaceted Nature of Aminopeptidases ERAP1, ERAP2, and LNPEP: From Evolution to Disease.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32793222","citation_count":34,"is_preprint":false},{"pmid":"7948026","id":"PMC_7948026","title":"Isolation and characterisation of an alternatively-spliced rat amelogenin cDNA: LRAP--a highly conserved, functional alternatively-spliced amelogenin?","date":"1994","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/7948026","citation_count":34,"is_preprint":false},{"pmid":"36496055","id":"PMC_36496055","title":"Identification of Reduced ERAP2 Expression and a Novel HLA Allele as Components of a Risk Score for Susceptibility to Liver Injury Due to Amoxicillin-Clavulanate.","date":"2022","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/36496055","citation_count":33,"is_preprint":false},{"pmid":"12958690","id":"PMC_12958690","title":"The small bovine amelogenin LRAP fails to rescue the amelogenin null phenotype.","date":"2003","source":"Calcified tissue international","url":"https://pubmed.ncbi.nlm.nih.gov/12958690","citation_count":33,"is_preprint":false},{"pmid":"32847031","id":"PMC_32847031","title":"A New ERAP2/Iso3 Isoform Expression Is Triggered by Different Microbial Stimuli in Human Cells. Could It Play a Role in the Modulation of SARS-CoV-2 Infection?","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/32847031","citation_count":32,"is_preprint":false},{"pmid":"29991817","id":"PMC_29991817","title":"An allelic variant in the intergenic region between ERAP1 and ERAP2 correlates with an inverse expression of the two genes.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29991817","citation_count":31,"is_preprint":false},{"pmid":"32210971","id":"PMC_32210971","title":"The Differential Expression of ERAP1/ERAP2 and Immune Cell Activation in Pre-eclampsia.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32210971","citation_count":27,"is_preprint":false},{"pmid":"31379846","id":"PMC_31379846","title":"Endoplasmic Reticulum Associated Aminopeptidase 2 (ERAP2) Is Released in the Secretome of Activated MDMs and Reduces in vitro HIV-1 Infection.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31379846","citation_count":27,"is_preprint":false},{"pmid":"19368031","id":"PMC_19368031","title":"Structure, orientation, and dynamics of the C-terminal hexapeptide of LRAP determined using solid-state NMR.","date":"2008","source":"The journal of physical chemistry. B","url":"https://pubmed.ncbi.nlm.nih.gov/19368031","citation_count":26,"is_preprint":false},{"pmid":"36889308","id":"PMC_36889308","title":"Variation in ERAP2 has opposing effects on severe respiratory infection and autoimmune disease.","date":"2023","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/36889308","citation_count":24,"is_preprint":false},{"pmid":"28083616","id":"PMC_28083616","title":"ERAP1 and ERAP2 Gene Variations Influence the Risk of Psoriatic Arthritis in Romanian Population.","date":"2017","source":"Archivum immunologiae et therapiae experimentalis","url":"https://pubmed.ncbi.nlm.nih.gov/28083616","citation_count":24,"is_preprint":false},{"pmid":"33717175","id":"PMC_33717175","title":"ERAP2 Increases the Abundance of a Peptide Submotif Highly Selective for the Birdshot Uveitis-Associated HLA-A29.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33717175","citation_count":23,"is_preprint":false},{"pmid":"33567739","id":"PMC_33567739","title":"ERAP1 and ERAP2 Enzymes: A Protective Shield for RAS against COVID-19?","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33567739","citation_count":22,"is_preprint":false},{"pmid":"31092671","id":"PMC_31092671","title":"Redundancy and Complementarity between ERAP1 and ERAP2 Revealed by their Effects on the Behcet's Disease-associated HLA-B*51 Peptidome.","date":"2019","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/31092671","citation_count":22,"is_preprint":false},{"pmid":"23477285","id":"PMC_23477285","title":"Neutron reflectometry studies of the adsorbed structure of the amelogenin, LRAP.","date":"2013","source":"The journal of physical chemistry. B","url":"https://pubmed.ncbi.nlm.nih.gov/23477285","citation_count":22,"is_preprint":false},{"pmid":"37925533","id":"PMC_37925533","title":"Evolutionary immuno-genetics of endoplasmic reticulum aminopeptidase II (ERAP2).","date":"2023","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/37925533","citation_count":21,"is_preprint":false},{"pmid":"23477367","id":"PMC_23477367","title":"Phosphorylation and ionic strength alter the LRAP-HAP interface in the N-terminus.","date":"2013","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23477367","citation_count":21,"is_preprint":false},{"pmid":"17959903","id":"PMC_17959903","title":"The effect of LRAP on enamel organ epithelial cell differentiation.","date":"2007","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/17959903","citation_count":21,"is_preprint":false},{"pmid":"27390066","id":"PMC_27390066","title":"Discovery of potent and selective inhibitors of human aminopeptidases ERAP1 and ERAP2 by screening libraries of phosphorus-containing amino acid and dipeptide analogues.","date":"2016","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/27390066","citation_count":21,"is_preprint":false},{"pmid":"24223975","id":"PMC_24223975","title":"Concerted in vitro trimming of viral HLA-B27-restricted ligands by human ERAP1 and ERAP2 aminopeptidases.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24223975","citation_count":21,"is_preprint":false},{"pmid":"34727153","id":"PMC_34727153","title":"ERAP1, ERAP2, and Two Copies of HLA-Aw19 Alleles Increase the Risk for Birdshot Chorioretinopathy in HLA-A29 Carriers.","date":"2021","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/34727153","citation_count":20,"is_preprint":false},{"pmid":"30794838","id":"PMC_30794838","title":"ERAP1-ERAP2 haplotypes are associated with ankylosing spondylitis in Polish patients.","date":"2019","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30794838","citation_count":20,"is_preprint":false},{"pmid":"26088389","id":"PMC_26088389","title":"ERAP2 functional knockout in humans does not alter surface heavy chains or HLA-B27, inflammatory cytokines or endoplasmic reticulum stress markers.","date":"2015","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/26088389","citation_count":19,"is_preprint":false},{"pmid":"35904863","id":"PMC_35904863","title":"Discovery of the First Selective Nanomolar Inhibitors of ERAP2 by Kinetic Target-Guided Synthesis.","date":"2022","source":"Angewandte Chemie (International ed. in English)","url":"https://pubmed.ncbi.nlm.nih.gov/35904863","citation_count":18,"is_preprint":false},{"pmid":"17679105","id":"PMC_17679105","title":"Enamel formation in vitro in mouse molar explants exposed to amelogenin polypeptides ATMP and LRAP on enamel development.","date":"2007","source":"Archives of oral biology","url":"https://pubmed.ncbi.nlm.nih.gov/17679105","citation_count":18,"is_preprint":false},{"pmid":"29769354","id":"PMC_29769354","title":"Allele-specific Alterations in the Peptidome Underlie the Joint Association of HLA-A*29:02 and Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) with Birdshot Chorioretinopathy.","date":"2018","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/29769354","citation_count":18,"is_preprint":false},{"pmid":"36203608","id":"PMC_36203608","title":"The emerging multifunctional roles of ERAP1, ERAP2 and IRAP between antigen processing and renin-angiotensin system modulation.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36203608","citation_count":17,"is_preprint":false},{"pmid":"19850130","id":"PMC_19850130","title":"The leucine rich amelogenin protein (LRAP) adsorbs as monomers or dimers onto surfaces.","date":"2009","source":"Journal of structural biology","url":"https://pubmed.ncbi.nlm.nih.gov/19850130","citation_count":17,"is_preprint":false},{"pmid":"23988446","id":"PMC_23988446","title":"EpCAM associates with endoplasmic reticulum aminopeptidase 2 (ERAP2) in breast cancer cells.","date":"2013","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/23988446","citation_count":17,"is_preprint":false},{"pmid":"33762660","id":"PMC_33762660","title":"Genetic association of ERAP1 and ERAP2 with eclampsia and preeclampsia in northeastern Brazilian women.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33762660","citation_count":16,"is_preprint":false},{"pmid":"29480940","id":"PMC_29480940","title":"ERAP1/ERAP2 and RUNX3 polymorphisms are not associated with ankylosing spondylitis susceptibility in Chinese Han.","date":"2018","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29480940","citation_count":16,"is_preprint":false},{"pmid":"32265295","id":"PMC_32265295","title":"Modulation of Natural HLA-B*27:05 Ligandome by Ankylosing Spondylitis-associated Endoplasmic Reticulum Aminopeptidase 2 (ERAP2).","date":"2020","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/32265295","citation_count":16,"is_preprint":false},{"pmid":"36716917","id":"PMC_36716917","title":"Cell-Specific and Variant-Linked Alterations in Expression of ERAP1, ERAP2, and LNPEP Aminopeptidases in Psoriasis.","date":"2023","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/36716917","citation_count":15,"is_preprint":false},{"pmid":"34642112","id":"PMC_34642112","title":"ERAP2 is a novel target involved in autophagy and activation of pancreatic stellate cells via UPR signaling pathway.","date":"2021","source":"Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/34642112","citation_count":13,"is_preprint":false},{"pmid":"25449314","id":"PMC_25449314","title":"The leucine-rich amelogenin protein (LRAP) is primarily monomeric and unstructured in physiological solution.","date":"2014","source":"Journal of structural biology","url":"https://pubmed.ncbi.nlm.nih.gov/25449314","citation_count":12,"is_preprint":false},{"pmid":"26607574","id":"PMC_26607574","title":"Truncated amelogenin and LRAP transgenes improve Amelx null mouse enamel.","date":"2015","source":"Matrix biology : journal of the International Society for Matrix Biology","url":"https://pubmed.ncbi.nlm.nih.gov/26607574","citation_count":12,"is_preprint":false},{"pmid":"35163832","id":"PMC_35163832","title":"ERAP2 Inhibition Induces Cell-Surface Presentation by MOLT-4 Leukemia Cancer Cells of Many Novel and Potentially Antigenic Peptides.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35163832","citation_count":12,"is_preprint":false},{"pmid":"20304108","id":"PMC_20304108","title":"A solution NMR investigation into the murine amelogenin splice-variant LRAP (Leucine-Rich Amelogenin Protein).","date":"2010","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/20304108","citation_count":12,"is_preprint":false},{"pmid":"25071599","id":"PMC_25071599","title":"The flexible structure of the K24S28 region of Leucine-Rich Amelogenin Protein (LRAP) bound to apatites as a function of surface type, calcium, mutation, and ionic strength.","date":"2014","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/25071599","citation_count":11,"is_preprint":false},{"pmid":"38190099","id":"PMC_38190099","title":"A cis-regulatory element regulates ERAP2 expression through autoimmune disease risk SNPs.","date":"2023","source":"Cell genomics","url":"https://pubmed.ncbi.nlm.nih.gov/38190099","citation_count":10,"is_preprint":false},{"pmid":"27277399","id":"PMC_27277399","title":"Leucine-Rich Amelogenin Peptide (LRAP) Uptake by Cementoblast Requires Flotillin-1 Mediated Endocytosis.","date":"2016","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/27277399","citation_count":10,"is_preprint":false},{"pmid":"27384923","id":"PMC_27384923","title":"Expression of ERAP2 and LST1 is increased before start of therapy in rheumatoid arthritis patients with good clinical response to glucocorticoids.","date":"2016","source":"Clinical and experimental rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/27384923","citation_count":8,"is_preprint":false},{"pmid":"35563348","id":"PMC_35563348","title":"A Short ERAP2 That Binds IRAP Is Expressed in Macrophages Independently of Gene Variation.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35563348","citation_count":8,"is_preprint":false},{"pmid":"31530632","id":"PMC_31530632","title":"Substantial Influence of ERAP2 on the HLA-B*40:02 Peptidome: Implications for HLA-B*27-Negative Ankylosing Spondylitis.","date":"2019","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/31530632","citation_count":8,"is_preprint":false},{"pmid":"36608422","id":"PMC_36608422","title":"ERAP2 supports TCR recognition of three immunotherapy targeted tumor epitopes.","date":"2023","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36608422","citation_count":7,"is_preprint":false},{"pmid":"37686141","id":"PMC_37686141","title":"ERAP1 and ERAP2 Haplotypes Influence Suboptimal HLA-B*27:05-Restricted Anti-Viral CD8+ T Cell Responses Cross-Reactive to Self-Epitopes.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37686141","citation_count":7,"is_preprint":false},{"pmid":"32917832","id":"PMC_32917832","title":"Association of ERAP2 polymorphisms in Colombian HLA-B27+ or HLA-B15+ patients with SpA and its relationship with clinical presentation: axial or peripheral predominance.","date":"2020","source":"RMD open","url":"https://pubmed.ncbi.nlm.nih.gov/32917832","citation_count":7,"is_preprint":false},{"pmid":"35514997","id":"PMC_35514997","title":"Can ERAP1 and ERAP2 Form Functional Heterodimers? A Structural Dynamics Investigation.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35514997","citation_count":6,"is_preprint":false},{"pmid":"36214762","id":"PMC_36214762","title":"ERAP2 as a potential biomarker for predicting gemcitabine response in patients with pancreatic cancer.","date":"2022","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/36214762","citation_count":6,"is_preprint":false},{"pmid":"30933316","id":"PMC_30933316","title":"Association of ERAP2 gene variants with risk of pre-eclampsia among Iranian women.","date":"2019","source":"International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics","url":"https://pubmed.ncbi.nlm.nih.gov/30933316","citation_count":6,"is_preprint":false},{"pmid":"38616723","id":"PMC_38616723","title":"ERAP1 and ERAP2 gene variants as potential clinical biomarkers of anti-interleukin-17A response in psoriasis vulgaris.","date":"2024","source":"Clinical and experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/38616723","citation_count":5,"is_preprint":false},{"pmid":"36569828","id":"PMC_36569828","title":"The ER Aminopeptidases, ERAP1 and ERAP2, synergize to self-modulate their respective activities.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36569828","citation_count":5,"is_preprint":false},{"pmid":"33309189","id":"PMC_33309189","title":"Synergy of endoplasmic reticulum aminopeptidase 1 and 2 (ERAP1 and ERAP2) polymorphisms in atopic dermatitis: Effects on disease prevalence.","date":"2020","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33309189","citation_count":5,"is_preprint":false},{"pmid":"39123229","id":"PMC_39123229","title":"The effect of rs2910686 on ERAP2 expression in IBD and epithelial inflammatory response.","date":"2024","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39123229","citation_count":4,"is_preprint":false},{"pmid":"35767698","id":"PMC_35767698","title":"Phenylsulfamoyl Benzoic Acid Inhibitor of ERAP2 with a Novel Mode of Inhibition.","date":"2022","source":"ACS chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/35767698","citation_count":4,"is_preprint":false},{"pmid":"39839670","id":"PMC_39839670","title":"Impact of endoplasmic reticulum aminopeptidases 1 (ERAP1) and 2 (ERAP2) on neutrophil cellular functions.","date":"2025","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/39839670","citation_count":4,"is_preprint":false},{"pmid":"31621902","id":"PMC_31621902","title":"Novel LRAP-binding partner revealing the plasminogen activation system as a regulator of cementoblast differentiation and mineral nodule formation in vitro.","date":"2019","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31621902","citation_count":4,"is_preprint":false},{"pmid":"38980912","id":"PMC_38980912","title":"Epistatic interaction between ERAP2 and HLA modulates HIV-1 adaptation and disease outcome in an Australian population.","date":"2024","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/38980912","citation_count":3,"is_preprint":false},{"pmid":"39906739","id":"PMC_39906739","title":"Association of ERAP1 and ERAP2 gene polymorphisms and ERAP2 protein with the susceptibility and severity of rheumatoid arthritis in the Ukrainian population.","date":"2025","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39906739","citation_count":3,"is_preprint":false},{"pmid":"38704785","id":"PMC_38704785","title":"A study of the association between single nucleotide polymorphisms of the endoplasmic reticulum aminopeptidase 2 (ERAP2) gene and the risk of ankylosing spondylitis in Egyptians.","date":"2024","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/38704785","citation_count":3,"is_preprint":false},{"pmid":"17129607","id":"PMC_17129607","title":"No association of type 1 diabetes with a functional polymorphism of the LRAP gene.","date":"2006","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17129607","citation_count":3,"is_preprint":false},{"pmid":"27590425","id":"PMC_27590425","title":"Polymorphisms in ERAP1 and ERAP2 are shared by Caninae and segregate within and between random- and pure-breeds of dogs.","date":"2016","source":"Veterinary immunology and immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/27590425","citation_count":2,"is_preprint":false},{"pmid":"41485621","id":"PMC_41485621","title":"ERAP2 inhibitor -incorporated nanofibers: Characterization and biological assessment.","date":"2026","source":"International journal of pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/41485621","citation_count":1,"is_preprint":false},{"pmid":"39910453","id":"PMC_39910453","title":"The important roles of ERAP1, ERAP2 genes polymorphisms and their DNA methylation levels in pulmonary tuberculosis.","date":"2025","source":"BMC infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/39910453","citation_count":1,"is_preprint":false},{"pmid":"40469972","id":"PMC_40469972","title":"The role of endoplasmic reticulum aminopeptidase ERAP2 pathogenic mutation rs1363907 in amoxicillin clavulanate-induced liver injury: a special case report.","date":"2025","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/40469972","citation_count":1,"is_preprint":false},{"pmid":"40226591","id":"PMC_40226591","title":"Unveiling the impact of ERAP1 and ERAP2 on migration, angiogenesis and ER stress response.","date":"2025","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/40226591","citation_count":0,"is_preprint":false},{"pmid":"41479007","id":"PMC_41479007","title":"Expression, Purification, and Functional Analysis Methods of Antigen-Processing Aminopeptidases ERAP1, ERAP2, and IRAP.","date":"2026","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/41479007","citation_count":0,"is_preprint":false},{"pmid":"41575441","id":"PMC_41575441","title":"The Impact of ERAP1 and ERAP2 Haplotype Combinations on Susceptibility and Severity of Birdshot Chorioretinitis.","date":"2026","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/41575441","citation_count":0,"is_preprint":false},{"pmid":"41428259","id":"PMC_41428259","title":"Rare and common variants in ERAP1 and ERAP2 selected for in response to Yersinia pestis infection contribute to autoimmune disease including inflammatory bowel disease.","date":"2025","source":"Mammalian genome : official journal of the International Mammalian Genome Society","url":"https://pubmed.ncbi.nlm.nih.gov/41428259","citation_count":0,"is_preprint":false},{"pmid":"41744933","id":"PMC_41744933","title":"Comparative Analysis of Amelogenin-Derived Peptides LRAP and SP on Osteogenic Differentiation of Human Dental Pulp and Bone Marrow-Derived Stem Cells.","date":"2026","source":"Dentistry journal","url":"https://pubmed.ncbi.nlm.nih.gov/41744933","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.09.08.674901","title":"The DNA virome varies with human genes and environments","date":"2025-09-11","source":"bioRxiv","url":"https://doi.org/10.1101/2025.09.08.674901","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.03.30.646199","title":"THE UNCHARTED ROLE OF ERAP2 IN AGING: A BIOINFORMATICS PERSPECTIVE","date":"2025-04-04","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.30.646199","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.05.22.25325739","title":"Identification of causal genes and mechanisms by which genetic variation mediates juvenile idiopathic arthritis susceptibility using functional genomics and CRISPR-Cas9","date":"2025-05-22","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.22.25325739","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.07.19.25331823","title":"Host control of latent Epstein-Barr virus infection","date":"2025-07-21","source":"bioRxiv","url":"https://doi.org/10.1101/2025.07.19.25331823","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52290,"output_tokens":6320,"usd":0.125835,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15126,"output_tokens":4640,"usd":0.095815,"stage2_stop_reason":"end_turn"},"total_usd":0.22165,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2005,\n      \"finding\": \"ERAP1 and ERAP2 form heterodimeric complexes in the endoplasmic reticulum and act with concerted, complementary aminopeptidase activities to trim N-terminally extended peptide precursors for HLA class I presentation; ERAP2 efficiently removed N-terminal residues that ERAP1 could not trim, and combined action was required both in vitro and in vivo for full processing of some epitopes.\",\n      \"method\": \"Co-localization in vivo, physical co-immunoprecipitation demonstrating heterodimer formation, in vitro peptide digestion assays comparing single vs. dual enzyme activity, cellular antigen presentation assays\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP establishing physical interaction, orthogonal in vitro and in vivo functional assays, foundational study replicated by multiple subsequent labs\",\n      \"pmids\": [\"15908954\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ERAP1-ERAP2 heterodimer formation increases peptide-trimming efficiency above that of a mixture of the two enzymes unable to dimerize; physical interaction with ERAP2 changes basic enzymatic parameters of ERAP1 and improves its substrate-binding affinity through allosteric effects.\",\n      \"method\": \"Production of stabilized ERAP1-ERAP2 heterodimers; comparison of peptide-trimming kinetics (epitope production) between heterodimers and non-dimerizing enzyme mixtures; enzymatic parameter measurement\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro reconstitution with stabilized heterodimers plus kinetic analysis, single lab but multiple orthogonal measurements of enzymatic parameters\",\n      \"pmids\": [\"24928998\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ERAP1/ERAP2 heterodimers can trim MHC class I-bound precursor peptides (not only free peptides) to their correct final lengths, albeit more slowly than free precursors; trimming of MHC I-bound precursors by ERAP1/2 increases the conformational stability of MHC I/peptide complexes.\",\n      \"method\": \"In vitro trimming assays using purified ERAP1/ERAP2 heterodimers with free and HLA-B*0801-bound N-terminally extended model and natural peptides; conformational stability measurements of MHC I/peptide complexes\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution assay with defined substrates (free and MHC-bound), heterodimer system, multiple peptide substrates tested\",\n      \"pmids\": [\"27514473\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"A splice variant of ERAP2 encoded by Haplotype B undergoes nonsense-mediated decay (NMD), resulting in ERAP2 protein deficiency; Haplotype B homozygotes have lower levels of MHC class I on B cell surfaces compared to Haplotype A homozygotes, demonstrating that naturally occurring ERAP2 deficiency affects MHC class I antigen presentation.\",\n      \"method\": \"Population genetic analysis of six human populations; RT-PCR demonstrating differential splicing; correlation of surface MHC class I expression with ERAP2 genotype in primary lymphocytes by flow cytometry\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genotype-phenotype correlation with functional cellular readout across multiple populations, splicing mechanism established by direct RT-PCR, replicated in independent cohorts\",\n      \"pmids\": [\"20976248\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ERAP1 and ERAP2 have significant and largely distinct effects on the HLA-B*27:05 peptidome in human cells; ERAP1 increases the proportion of nonamers relative to longer ligands and reduces Ala1 usage, while ERAP2 (in a low-activity ERAP1 context) additionally reduces peptides with N-terminal basic residues and lowers overall peptidome affinity. Both enzymes largely act as separate entities in vivo rather than obligate partners.\",\n      \"method\": \"Quantitative mass spectrometry comparison of HLA-B*27:05 peptidomes from cells with various ERAP1/ERAP2 phenotypes; label-free quantitative proteomics\",\n      \"journal\": \"Journal of autoimmunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — quantitative immunopeptidomics in live cells with multiple ERAP phenotype combinations, replicated across cell lines with different genetic backgrounds\",\n      \"pmids\": [\"28063628\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ERAP2 deletion from HLA-B*51:01-expressing cells by CRISPR/Cas9 reduces HLA-B*51 surface expression and alters the B*51:01 peptidome; in the absence of ERAP1, ERAP2 alone shows significant processing of B*51:01 ligands (functional redundancy), but effects of each enzyme differ substantially, revealing mutual dependence and partially redundant roles.\",\n      \"method\": \"CRISPR/Cas9 knockout of ERAP1, ERAP2, or both in transfectant 721.221-HLA-B*51:01 cells; label-free quantitative mass spectrometry comparison of HLA-B*51:01 peptidomes\",\n      \"journal\": \"Molecular & cellular proteomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean CRISPR KO with reciprocal single and double knockouts, quantitative immunopeptidomics, multiple orthogonal comparisons\",\n      \"pmids\": [\"31092671\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ERAP2 expression alters the HLA-A*29:02 peptidome by increasing peptides >9-mers and shifting N-terminal residue composition toward less ERAP2-susceptible and more hydrophobic residues; unproductive ERAP2 binding may protect some peptides from ERAP1 over-trimming. ERAP2 effects are allele-specific and differ from its effects on HLA-B*27.\",\n      \"method\": \"Lentiviral transduction of ERAP2 into ERAP2-negative cells; label-free quantitative mass spectrometry of A*29:02-bound peptidomes; comparison across two independent A*29:02-positive cell lines\",\n      \"journal\": \"Molecular & cellular proteomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — gain-of-function lentiviral system with quantitative immunopeptidomics, replicated in two independent cell line comparisons\",\n      \"pmids\": [\"29769354\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ERAP2 CRISPR knockout in cells expressing HLA-B*27:05 alters the natural ligandome: absence of ERAP2 enriches peptides with N-terminal basic residues and minority canonical P2 residues, and affects hydrophobicity profiles at P3, P7, and PΩ positions; one ERAP2-dependent human peptide was found fully conserved in a Campylobacter jejuni protein (potential molecular mimicry).\",\n      \"method\": \"CRISPR/Cas9 editing of ERAP2 in human cells; high-throughput and quantitative tandem mass spectrometry of HLA-B*27:05-bound peptidome; bioinformatics sequence alignment to arthritogenic bacteria\",\n      \"journal\": \"Molecular & cellular proteomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean CRISPR KO with quantitative immunopeptidomics, single lab, multiple analytical approaches\",\n      \"pmids\": [\"32265295\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The optimal ligands for ERAP1 (octamers) act as competitive inhibitors of ERAP2 activity, while peptides longer than nonamers inhibit ERAP1; ERAP1 and ERAP2 thus synergize to self-modulate their respective activities and jointly shape the MHC-I peptidome toward optimal peptide lengths.\",\n      \"method\": \"Biochemical inhibition assays with defined peptide substrates; proteomic studies; biological verification of inhibition model\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Weak — in vitro biochemical and proteomic data from single lab, mechanism supported but limited independent replication\",\n      \"pmids\": [\"36569828\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ERAP1 and ERAP2 show concerted in vitro trimming of HLA-B27-restricted viral ligand precursors: each enzyme can use the degradation products of the other as substrates, resulting in increased detection of natural HLA-B27 ligands with combined versus single enzyme digestion.\",\n      \"method\": \"In vitro peptide digestion comparing single ERAP1, single ERAP2, and combined ERAP1+ERAP2 digestions; mass spectrometry identification of peptide products\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro reconstitution assay with mass spectrometry readout, single lab, limited substrate set\",\n      \"pmids\": [\"24223975\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ERAP2 depletion (CRISPR KO) from HLA-B*40:02-expressing cells induces significant quantitative changes in the HLA-B*40:02 peptidome; the major effect is on N-terminal residue frequencies—basic and small residues increased, aliphatic/aromatic decreased—consistent with ERAP2's preferential trimming of N-terminal basic residues.\",\n      \"method\": \"CRISPR/Cas9 knockout of ERAP2 in C1R-B*40:02 transfectant cells; label-free quantitative mass spectrometry comparison of wildtype vs. ERAP2-KO peptidomes\",\n      \"journal\": \"Molecular & cellular proteomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean CRISPR KO, quantitative immunopeptidomics, mechanistic characterization of substrate preferences, single lab\",\n      \"pmids\": [\"31530632\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ERAP2 generates a peptide submotif specifically bound by HLA-A29 (not by other HLA allotypes tested); this ERAP2-dependent peptide motif is present in sequences of putative autoantigens, and ERAP2 imprints internal sequence specificity in the immunopeptidome.\",\n      \"method\": \"HLA-A29-based and pan-class I immunopurifications in patient-derived antigen-presenting cells; isotope-labeled quantitative mass spectrometry of naturally processed and presented HLA-bound peptides; replicated in independent datasets\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — quantitative immunopeptidomics in patient-derived cells, findings replicated in independent experiment, multiple HLA allotype comparisons\",\n      \"pmids\": [\"33717175\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ERAP2 inhibition with a selective small-molecule inhibitor in MOLT-4 leukemia cells induces significant shifts in the MHC class I immunopeptidome; >20% of detected peptides were novel or significantly upregulated, with most inhibitor-induced peptides being 9-mers with appropriate HLA-binding motifs, providing evidence that ERAP2 enzymatic activity shapes the cancer cell immunopeptidome.\",\n      \"method\": \"Pharmacological ERAP2 inhibition in MOLT-4 cells; MHC class I immunopurification; LC-MS/MS sequencing of bound peptides\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — pharmacological perturbation with quantitative immunopeptidomics, single lab, inhibitor selectivity relied on prior validation\",\n      \"pmids\": [\"35163832\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Crystal structure of ERAP2 bound to a novel phenylsulfamoyl benzoic acid inhibitor (compound 61) revealed it binds near the catalytic center at a site distinct from peptidomimetic inhibitors and inhibits by an uncompetitive mechanism; active-site residue specificity determinants were identified: His904 in an allosteric site of ERAP2 governs binding and the absence of activation by compound 3 (H904A mutation reveals a cryptic allosteric site), while ERAP1 Lys380 in the S1' pocket governs binding of related compounds.\",\n      \"method\": \"Co-crystallization and X-ray crystal structure determination of ERAP2-inhibitor complex; enzyme kinetics (uncompetitive mechanism); site-directed mutagenesis of active site and allosteric residues\",\n      \"journal\": \"ACS chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure plus mutagenesis plus kinetic mechanism determination in a single study, multiple orthogonal methods\",\n      \"pmids\": [\"35767698\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Kinetic target-guided synthesis identified the first nanomolar, selective ERAP2 inhibitors; co-crystallization experiments revealed the binding mode of three inhibitors with increasing potency and selectivity; selected compounds engage ERAP2 in cells and inhibit antigen presentation in a cellular context.\",\n      \"method\": \"Kinetic target-guided synthesis; co-crystallization with X-ray structure determination; cellular ERAP2 engagement assays; cellular antigen presentation inhibition assays\",\n      \"journal\": \"Angewandte Chemie\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structures plus cellular functional assays, multiple inhibitor structures determined, single lab but orthogonal methods\",\n      \"pmids\": [\"35904863\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ERAP2 knockdown in pancreatic stellate cells inhibits unfolded protein response (UPR)-mediated autophagy, leading to PSC inactivation and attenuation of IL-6 and fibronectin production; in vivo, ERAP2 knockdown in PSCs inhibited xenograft tumor growth and fibrosis.\",\n      \"method\": \"siRNA knockdown of ERAP2 in patient-derived pancreatic stellate cells; measurement of UPR markers, autophagy, IL-6, and fibronectin; orthotopic xenograft mouse model with ERAP2-knockdown PSCs\",\n      \"journal\": \"Pancreatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — loss-of-function with defined cellular and in vivo phenotype, single lab, pathway (UPR-autophagy) established but upstream mechanism linking ERAP2 aminopeptidase activity to UPR not fully elucidated\",\n      \"pmids\": [\"34642112\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ERAP2 is secreted from activated macrophages (stimulated with IFNγ/LPS) as detected by mass spectrometry of the secretome; the secreted full-length recombinant ERAP2 reduces HIV-1 replication in PBMCs in vitro (statistically significant), associated with increased IFNγ and CD69 expression and increased perforin-expressing CD107+CD8+ T cells.\",\n      \"method\": \"Mass spectrometry of MDM secretome after IFNγ/LPS stimulation; addition of recombinant human ERAP2 to PBMC cultures; HIV-1 p24 viral antigen quantification; flow cytometry for T cell markers\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Weak — mass spectrometry confirms secretion, functional anti-HIV effect demonstrated in vitro with recombinant protein, single lab\",\n      \"pmids\": [\"31379846\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ERAP2 expression is directly regulated by the splice region variant rs2248374 (established by reciprocal allelic replacement); disease-associated variants in the downstream LNPEP gene promoter independently regulate ERAP2 expression through long-range chromatin contacts, with allele-specific conformation capture assays showing stronger LNPEP-ERAP2 promoter interactions in autoimmune disease-risk allele carriers.\",\n      \"method\": \"Reciprocal allelic replacement (CRISPR-based); allele-specific chromosome conformation capture (4C/Hi-C); ERAP2 expression quantification by allele replacement\",\n      \"journal\": \"Cell genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal allelic replacement establishes direct causal link, complemented by chromatin conformation capture, two independent regulatory mechanisms identified\",\n      \"pmids\": [\"38190099\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"An alternative ERAP2 isoform (ERAP2/Iso3) is expressed from the rs2248374-G haplotype in response to multiple microbial stimuli (influenza, LPS, CMV, HIV, SARS-CoV-2 antigens); unlike ERAP2-wt, ERAP2/Iso3 is unable to trim peptides for MHC class I loading but can still dimerize with both ERAP2-wt and ERAP1-wt; ERAP2/Iso3 mRNA is translated into protein.\",\n      \"method\": \"RT-qPCR of ERAP2/Iso3 mRNA in stimulated PBMCs and MDMs; western blot confirmation of protein translation; in vitro peptide trimming assay demonstrating loss of function; dimerization assessment\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Weak — mRNA and protein confirmed, loss-of-trimming function established, dimerization capacity reported, single lab\",\n      \"pmids\": [\"32847031\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Macrophages (but not monocytes or other blood mononuclear cells) express and secrete an ERAP2 'short' form independent of haplotype; this short form is generated by autocatalytic cleavage within a distinctive structural motif requiring an acidic microenvironment; the short ERAP2 binds IRAP and both molecules are co-expressed in endosomes and on the cell membrane.\",\n      \"method\": \"Western blot detecting short ERAP2 form in macrophage lysates and secretome; autocatalytic cleavage demonstrated with recombinant protein under acidic conditions; co-immunoprecipitation of short ERAP2 with IRAP; co-localization by immunofluorescence in endosomes and cell membrane\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Weak — autocatalytic mechanism supported biochemically, IRAP binding by Co-IP, co-localization data, single lab\",\n      \"pmids\": [\"35563348\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"EpCAM co-immunoprecipitates with ERAP2 in breast cancer cell lines and the two proteins co-localize in the cytoplasm/ER and at the plasma membrane; in vitro expression in ER vesicles confirmed N-linked glycosylation and ER processing of EpCAM, suggesting ERAP2 may regulate EpCAM processing.\",\n      \"method\": \"Co-immunoprecipitation followed by mass spectrometry; in vitro expression in dog pancreas rough microsomes (ER vesicles); co-localization imaging\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single Co-IP/MS identification, no functional validation of the interaction's consequence, single lab\",\n      \"pmids\": [\"23988446\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"A regulatory variant (rs75862629 G vs. A) in the ERAP2 gene promoter region inversely coordinates expression of ERAP1 and ERAP2: presence of G at this SNP results in down-modulation of ERAP2 coupled with significantly higher ERAP1 expression in B-lymphoblastoid cell lines.\",\n      \"method\": \"Correlation of ERAP1 and ERAP2 transcript and protein levels with promoter region SNP genotype across 44 B-lymphoblastoid cell line donors; quantitative RT-PCR and protein quantification\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — expression quantification correlated with genotype across 44 donors, both mRNA and protein measured, but causal mechanism not directly tested by allelic replacement\",\n      \"pmids\": [\"29991817\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ERAP2, when expressed alone in ERAP-deficient cells, elicits a strong CTL response to the Tyrosinase368-376 HLA-A*02:01-restricted tumor epitope; ERAP2 alone can process TAP-dependent N-terminally extended epitope precursors of Tyrosinase368-376 in vitro; ERAP2 also independently enhances T cell recognition of gp100209-217 and MART-126/27-35 epitopes in the absence of ERAP1.\",\n      \"method\": \"Expression of ERAP2 alone in ERAP-deficient cells; CTL activation assays; in vitro peptide trimming assays with defined precursor peptides; T cell recognition assays\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — in vitro trimming plus cellular CTL assay, multiple epitopes tested, single lab\",\n      \"pmids\": [\"36608422\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ERAP2 is an ER-resident zinc aminopeptidase that trims N-terminally extended peptide precursors for MHC class I loading, with preferential activity toward peptides bearing N-terminal basic residues and toward shorter (<9-mer) substrates; it physically associates with ERAP1 to form heterodimers that exhibit enhanced trimming efficiency and allosterically modified ERAP1 kinetics, and can also trim MHC-I-bound precursors directly, with the two enzymes showing largely distinct but partially redundant and mutually inhibitory activities that together optimize the HLA class I immunopeptidome in an allotype-specific manner; expression of ERAP2 is controlled by a splice-region variant (rs2248374) causing nonsense-mediated decay of one haplotype, and by long-range chromatin contacts from the LNPEP promoter region; additionally, a macrophage-specific autocatalytically generated short form of ERAP2 binds IRAP in endosomes and at the cell membrane, and ERAP2 can be secreted extracellularly where it modulates immune responses including reducing HIV-1 replication.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ERAP2 is an endoplasmic reticulum-resident zinc aminopeptidase that trims N-terminally extended peptide precursors to optimize the HLA class I immunopeptidome [#0, #5]. It acts in concert with ERAP1, forming heterodimers in the ER whose assembly increases trimming efficiency above that of the unassociated enzymes and allosterically improves ERAP1 substrate-binding affinity [#0, #1]; the heterodimer can trim not only free precursors but also MHC class I-bound precursors, increasing the conformational stability of the resulting MHC/peptide complexes [#2]. Functionally, ERAP2 shows a characteristic preference for removing N-terminal basic residues, and its activity is largely distinct from, yet partially redundant with, that of ERAP1 — each enzyme can consume the other's products, and their optimal substrates competitively inhibit one another so that the two activities self-modulate toward optimal peptide lengths [#9, #8, #10]. Across multiple HLA allotypes (B*27:05, A*29:02, B*51:01, B*40:02), ERAP2 perturbation reshapes N-terminal residue usage, peptide length distributions, and overall binding affinity, and ERAP2 alone can generate functional tumor and viral epitopes in the absence of ERAP1, including imprinting allotype-restricted internal sequence motifs [#4, #6, #5, #7, #11, #23]. ERAP2 expression is genetically controlled: the splice-region variant rs2248374 directs a haplotype B transcript to nonsense-mediated decay, producing protein deficiency that lowers surface MHC class I, and disease-associated variation in the downstream LNPEP promoter independently regulates ERAP2 via long-range chromatin contacts [#3, #17]. Beyond canonical antigen processing, a macrophage-specific short form of ERAP2 is generated by autocatalytic cleavage under acidic conditions and binds IRAP in endosomes and at the cell membrane, and full-length ERAP2 is secreted from activated macrophages where it reduces HIV-1 replication in PBMCs [#19, #16]. Crystallographic and inhibitor studies have defined ERAP2 active-site and allosteric determinants and yielded selective nanomolar inhibitors that engage the enzyme in cells and block antigen presentation [#13, #14].\",\n  \"teleology\": [\n    {\n      \"year\": 2005,\n      \"claim\": \"Established that ERAP2 is not an isolated aminopeptidase but physically partners with ERAP1 to complete peptide trimming, answering how distinct trimming specificities are integrated for HLA class I presentation.\",\n      \"evidence\": \"Co-localization, reciprocal Co-IP, in vitro digestion, and cellular antigen presentation assays\",\n      \"pmids\": [\"15908954\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and structural basis of the heterodimer not resolved\", \"Did not quantify allosteric kinetic changes\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Showed that a naturally occurring splice variant routes one ERAP2 haplotype to NMD, defining the genetic basis of ERAP2 deficiency and linking it to reduced surface MHC class I.\",\n      \"evidence\": \"Population genetics, RT-PCR splicing analysis, and flow cytometry of surface MHC I across genotypes\",\n      \"pmids\": [\"20976248\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific epitopes lost in deficiency not mapped\", \"Mechanism by which deficiency alters disease risk not addressed\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstrated concerted, sequential processing in which each enzyme uses the other's products, clarifying how ERAP1 and ERAP2 cooperate at the substrate level.\",\n      \"evidence\": \"In vitro single vs. combined ERAP1/ERAP2 digestion with MS product identification; Co-IP/MS in breast cancer cells for an EpCAM interaction\",\n      \"pmids\": [\"24223975\", \"23988446\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Limited substrate set in trimming assays\", \"EpCAM interaction is a single Co-IP/MS without functional validation\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Reconstitution of stabilized heterodimers established that dimerization itself, not mere enzyme co-presence, enhances trimming and allosterically reshapes ERAP1 kinetics.\",\n      \"evidence\": \"Stabilized ERAP1-ERAP2 heterodimers vs. non-dimerizing mixtures with kinetic measurement\",\n      \"pmids\": [\"24928998\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo prevalence of heterodimers vs. monomers not quantified\", \"Structural interface not defined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Extended ERAP function to MHC-bound precursors, showing trimming can occur on loaded complexes and improves their stability, refining the timing of editing in the loading pathway.\",\n      \"evidence\": \"In vitro trimming of free and HLA-B*0801-bound precursors with conformational stability assays\",\n      \"pmids\": [\"27514473\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative in vivo contribution of bound vs. free trimming unknown\", \"Single HLA allotype tested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined ERAP2's allotype-specific imprint on the immunopeptidome, showing largely distinct effects from ERAP1 and a possible protective role against ERAP1 over-trimming.\",\n      \"evidence\": \"Quantitative immunopeptidomics of HLA-B*27:05 and HLA-A*29:02 with ERAP perturbation across cell lines\",\n      \"pmids\": [\"28063628\", \"29769354\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of 'unproductive binding' protection inferred, not directly shown\", \"Effects compared across only a few allotypes\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"CRISPR knockouts across multiple HLA allotypes nailed ERAP2's substrate signature — preferential N-terminal basic-residue trimming — and revealed partial redundancy with mutual dependence on ERAP1.\",\n      \"evidence\": \"Reciprocal CRISPR KO of ERAP1/ERAP2 in HLA-B*51:01 and B*40:02 cells with quantitative immunopeptidomics\",\n      \"pmids\": [\"31092671\", \"31530632\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of substrate preference not structurally explained here\", \"Functional consequences for T-cell repertoire not measured\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified non-canonical ERAP2 biology: a microbially induced, trimming-dead isoform that still dimerizes, and a UPR/autophagy-linked role in pancreatic stellate cells.\",\n      \"evidence\": \"RT-qPCR/western of ERAP2/Iso3 with trimming and dimerization assays; siRNA knockdown in PSCs with xenograft model\",\n      \"pmids\": [\"32847031\", \"34642112\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional purpose of trimming-dead Iso3 dimers unknown\", \"How ERAP2 aminopeptidase activity links to UPR/autophagy not mechanistically established\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed ERAP2 imprints internal (not just N-terminal) sequence specificity, generating allotype-restricted submotifs relevant to autoantigen presentation.\",\n      \"evidence\": \"Quantitative immunopeptidomics in patient-derived APCs across HLA allotypes, replicated\",\n      \"pmids\": [\"33717175\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Causal link between submotif and autoimmunity not established\", \"Restricted to HLA-A29 context\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Resolved the self-modulation logic: ERAP1's optimal substrates inhibit ERAP2 and vice versa, explaining how the pair converges on optimal peptide lengths.\",\n      \"evidence\": \"Biochemical inhibition assays with defined peptides plus proteomic verification\",\n      \"pmids\": [\"36569828\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab, limited independent replication\", \"Inhibition constants in cellular context not measured\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Structural and inhibitor work defined ERAP2 active-site and allosteric determinants and produced selective cell-active inhibitors, enabling pharmacological dissection of ERAP2 in antigen presentation.\",\n      \"evidence\": \"Co-crystallization, enzyme kinetics, site-directed mutagenesis, and cellular engagement/antigen presentation assays\",\n      \"pmids\": [\"35767698\", \"35904863\", \"35163832\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Inhibitor effects on full immunopeptidome only partially mapped\", \"Allosteric site His904 function beyond compound binding unclear\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Characterized extracellular and macrophage-specific ERAP2 forms, expanding its role beyond intracellular peptide editing to secreted immunomodulation and IRAP binding.\",\n      \"evidence\": \"Secretome MS, recombinant ERAP2 anti-HIV assays in PBMCs, autocatalytic cleavage and IRAP Co-IP/co-localization in macrophages\",\n      \"pmids\": [\"31379846\", \"35563348\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of extracellular anti-HIV action not defined\", \"Physiological function of the short ERAP2-IRAP complex unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstrated that ERAP2 alone can generate functional tumor epitopes, establishing an ERAP1-independent contribution to CTL recognition.\",\n      \"evidence\": \"ERAP2 expression in ERAP-deficient cells, in vitro precursor trimming, and CTL/T-cell recognition assays for Tyrosinase, gp100, and MART-1 epitopes\",\n      \"pmids\": [\"36608422\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Breadth of ERAP2-independent epitope generation across tumors not assessed\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Established two independent causal regulatory mechanisms for ERAP2 expression — the rs2248374 splice variant and long-range LNPEP promoter chromatin contacts — connecting expression control to autoimmune disease risk.\",\n      \"evidence\": \"Reciprocal CRISPR allelic replacement and allele-specific chromosome conformation capture\",\n      \"pmids\": [\"38190099\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream immune consequences of altered expression in carriers not measured\", \"Interplay between the two regulatory mechanisms not resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How ERAP2's multiple non-canonical activities — secreted immunomodulation, the IRAP-bound macrophage short form, trimming-dead dimerizing isoforms, and UPR/autophagy effects — integrate with its core role in MHC class I peptide editing remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No unified model connecting intracellular trimming and extracellular/non-canonical roles\", \"Physiological relevance of macrophage short form and IRAP complex undefined\", \"Mechanistic basis of UPR/autophagy link untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 2, 9, 10, 23]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 1, 9, 13]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [1, 8]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [0, 2, 20]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [19]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [19, 20]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [16, 19]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 3, 4, 5, 16]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [0, 2, 9]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [3, 17]}\n    ],\n    \"complexes\": [\"ERAP1-ERAP2 heterodimer\"],\n    \"partners\": [\"ERAP1\", \"IRAP\", \"EpCAM\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":7,"faith_total":7,"faith_pct":100.0}}